Resistance to the antimalarial drug artemisinin is established in Myanmar and has reached within 25km of the Indian border, a study published today in Lancet Infectious Diseases reports. Artemisinin resistance threatens to follow the same historical trajectory from Southeast Asia to the Indian subco...

Speical supplement from American Journal of Hygiene and Tropical Medicine focussess on the proliferation of falsified medicines.

Drug-resistant malaria parasites have spread to critical border regions of Southeast Asia, seriously threatening global malaria control and elimination programmes, according to a study published in the New England Journal of Medicine.

London seminar commemorating World Malaria Day 2015 explores how we can best ‘Invest in the future: defeat malaria’

Published in BMC Medicine, Prof Carol Sibley’s commentary piece explores the rare opportunity to observe the early stages of drug resistance in malaria parasites.

A study published in the BMC Medicine presents evidence that AS-AQ remains a highly effective malaria treatment in many settings, particularly in sub-Saharan Africa. The study showed that the efficacy of the medicine does, however, vary due to changes in the formulation of the two parts of the ACT, ...

A recent study published in the WHO Bulletin, led by Drs Daniel Hayes and Anja Terlouw at the Liverpool School of Tropical Medicine in the UK, has compiled the first ever robust analysis of actual bodyweight distribution in Africa, Asia and Latin America, and provided suitable regional weight-for-ag...

The latest results published by our AL Dose Impact Study Group confirm that the current recommended dose of artemether-lumefantrine (AL) – a leading antimalarial treatment – is still working very well in patients treated for malaria. However, the analyses of data from more than 14,000 patients also ...

Professor Chris Plowe, the longtime Head of the WWARN Molecular Group is busy with his new role as President of the American Society of Tropical Medicine and Hygiene in the USA.

The WWARN Network has initiated a series of pooled analyses of individual patient data to assess the risk factors associated with recurring malaria infection after treatment with the three main ACTs; artemether-lumefantrine (AL), artesunate-amodiaquine (ASAQ) and dihydroartemisinin-piperaquine (DP).

WWARN's Head of Drug Quality, Professor Paul Newton, and colleagues* published important recommendations in the British Medical Journal